|Articles|June 1, 2014

EU Steps Up Manufacturing Inspection Efforts

One of EMA’s key objectives this year is improvements in dealing with the “causes and impact of shortages of human medicines caused by GMP non-compliance and quality defects”.

One of EMA’s key objectives this year is improvements in dealing with the “causes and impact of shortages of human medicines caused by GMP non-compliance and quality defects”. The European Directorate for the Quality of Medicines & Healthcare, which is responsible for the European Pharmacopoeia but also runs its own inspection operations, has been tightening and updating guidelines on the testing of products.

Pharm Tech‘s Sean Milmo explains how in this article.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related to this article

September 22nd, 2026

Pharmaceutical Executive Daily: Nine European Drugmakers Note Concern Over Region's Pharma Investments

Nine major European drugmakers warn the region risks losing pharma investment, Novartis licenses a preclinical radioligand therapy asset from BoomRay Pharmaceuticals, and Rafaat Rahmani argues that the costliest competitive intelligence failure is missing the moment a strategic assumption goes wrong.

September 22nd, 2026

The Most Expensive CI Failure is Missing the Moment Your Strategic Assumption Became Wrong

The best CI partner isn't the one with the most data — it's the one willing to tell you your assumptions are wrong.

September 22nd, 2026

Nine European Drugmakers Warn the Continent Risks Losing the Pharma Investment Race: Report

Chairs of Europe's largest drugmakers urge the EU to boost health spending, speed up clinical trials, and strengthen IP protections before falling further behind the US and China.

September 22nd, 2026

Novartis & BoomRay Enter Global License Agreement for Preclinical Radioligand Asset

Novartis has agreed to pay BoomRay up to $900 million for exclusive global rights to an undisclosed preclinical radioligand therapy asset.

September 22nd, 2026

How Recent FDA Actions Impact Sponsors

Inovalon's Jen Lamppa on why FDA's acceptance of RWD downstream is a call to action for sponsors to start using it upstream in trial design.

September 21st, 2026

Pharmaceutical Executive Daily: AbbVie Forms Ai-Powered Drug Discovery Partnership with Iambic

AbbVie partners with Iambic on AI-driven drug discovery as Telix Pharmaceuticals moves to acquire ITM Isotope Technologies in a multibillion-dollar radiopharmaceutical merger, Novo Nordisk's CagriSema outperforms Eli Lilly's tirzepatide in a head-to-head diabetes trial, and Jen Lamppa of Inovalon discusses how real-time clinical data is reshaping trial recruitment.

September 21st, 2026

Roundup: AbbVie & Iambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM

AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.

September 21st, 2026

CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report

Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.

EU Steps Up Manufacturing Inspection Efforts

Related to this article

Trending on PharmExec

CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report

Novartis & BoomRay Enter Global License Agreement for Preclinical Radioligand Asset

How Recent FDA Actions Impact Sponsors

Pharmaceutical Executive Daily: AbbVie Forms Ai-Powered Drug Discovery Partnership with Iambic

Nine European Drugmakers Warn the Continent Risks Losing the Pharma Investment Race: Report